Wall Street Capital Markets Veteran and
Recognized All-Star Bio-Medical Technology Analyst joins Tivic
Health’s Governance Team
Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a
health tech company that develops and commercializes bioelectronic
medicine, is pleased to welcome Christina Valauri to its board of
directors, effective July 1, 2024.
Ms. Valauri has served as a strategic advisor to the company
since April 2023, and brings over 30-years of experience as a
seasoned capital markets professional with extensive analytical and
management experience. Ms. Valauri has a proven track record as a
senior healthcare analyst, US and Global Head of Equity Research,
senior broker-dealer manager, strategic business consultant, and
board director and advisor. As a managing director and senior
manager within capital markets, she has successfully developed and
executed transformational business strategies in the US and
internationally to drive growth, and provide enhanced operating
performance and comprehensive regulatory and supervisory oversight.
She has held leadership roles at US and international firms,
including as the Global Director of Research at Cantor Fitzgerald,
and senior research management roles at Credit Lyonnais, ING and
Natixis.
Ms. Valauri’s career in equity securities research expands the
Tivic boards’ deep expertise in pharmaceutical, biotech, and
med-tech industries. She has extensive experience identifying and
analyzing the commercial potential of breakthrough innovations, as
well as mentoring and advising C-suite teams of private and public
early-stage healthcare companies through product development,
regulatory, go-to-market strategies, potential mergers and
acquisitions, and IPOs.
Ms. Valauri currently serves as an Entrepreneur in Residence at
Weill Cornell Medicine BioVenture eLab, where she applies her
skills and experience in life sciences and business. She supports
and facilitates the organization’s mission to foster an
entrepreneurial ecosystem related to the innovations of researchers
and clinicians. Ms. Valauri is the founder and CEO of Sagestone
Advisory, LLC., and also serves as a senior advisor with Hanover
International, Inc. and Astia.org. She has been recognized by The
Wall Street Journal’s “Best on The Street” All-Star Analyst Survey
and has received the Award for Excellence in Medical Education
Public Affairs - Association of American Medical Colleges. Ms.
Valauri earned her BA in Biology from Reed College and an MBA from
Cornell University.
“Over the past year, as an advisor to our Board and the company,
Christina Valauri has demonstrated deep commitment to excellence
and the highest standards of ethical governance. This, paired with
her insight into capital markets and deep background in research
analysis, is a powerful combination to help ensure we make the best
decisions for the company, our customers and our shareholders,”
stated Sheryle Bolton, Chair of the Board.
“I could not be more excited that Christina has agreed to serve
on our board of directors, particularly as we forge new segments in
our bioelectronic portfolio, focused on precision modulation of
vagus nerve activity,” shared Jennifer Ernst, Chief Executive
Officer of Tivic Health.
Additionally, independent director, Karen Drexler, tendered her
resignation from the board and the committees thereof, effective
September 30, after which she will be continuing with the company
as a strategic advisor. Ms. Drexler previously served as an advisor
to the company from August 2017 through August 2019 when she joined
Tivic Health’s board as the company’s first independent director.
Ernst continued, “Karen was an instrumental force in the early
formation of Tivic Health. I deeply appreciate her commitment to
Tivic Health’s development for the past eight years and her
continued support as a strategic advisor to the company.”
About Tivic Health
Tivic Health is a commercial health tech company advancing the
field of bioelectronic medicine. Tivic Health’s patented technology
platform leverages stimulation on the trigeminal, sympathetic, and
vagus nerve structures. Tivic Health’s non-invasive and targeted
approach to the treatment of inflammatory chronic health conditions
gives consumers and providers drug-free therapeutic solutions with
high safety profiles, low risk, and broad applications. Tivic
Health’s first commercial product ClearUP is an FDA approved,
award-winning, handheld bioelectronic sinus device. ClearUP is
clinically proven, doctor-recommended, and is available through
online retailers and commercial distributors. For more information
visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: statements regarding the expansion
of Tivic Health’s product portfolio; changes in board composition;
Ms. Drexler’s service as an advisor to the company; market and
other conditions; macroeconomic factors, including inflation; and
unexpected costs, charges or expenses that reduce Tivic Health’s
capital resources. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking
statements. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause Tivic Health’s
actual results to differ from those contained in the
forward-looking statements, see Tivic Health’s filings with the
SEC, including, its Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the SEC on March 29, 2024, under the
heading “Risk Factors”; as well as the company’s subsequent filings
with the SEC. Forward-looking statements contained in this press
release are made as of this date, and Tivic Health Systems, Inc.
undertakes no duty to update such information except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618967001/en/
Media Contact: Morgan Luke
Morgan.Luke@tivichealth.com
Investor Contact: Hanover International, Inc.
ir@tivichealth.com
Grafico Azioni Tivic Health Systems (NASDAQ:TIVC)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Tivic Health Systems (NASDAQ:TIVC)
Storico
Da Gen 2024 a Gen 2025
